Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

A myeloid tumor suppressor role for NOL3.

Stanley RF, Piszczatowski RT, Bartholdy B, Mitchell K, McKimpson WM, Narayanagari S, Walter D, Todorova TI, Hirsch C, Makishima H, Will B, McMahon C, Gritsman K, Maciejewski JP, Kitsis RN, Steidl U.

J Exp Med. 2017 Mar 6;214(3):753-771. doi: 10.1084/jem.20162089. Epub 2017 Feb 23.

2.

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL.

PLoS Med. 2006 Jul;3(7):e270.

3.

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.

Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, Hricik T, Bhagwat N, McKenney AS, Papalexi E, Abdel-Wahab O, Rampal R, Marubayashi S, Chen JJ, Romanet V, Fridman JS, Bromberg J, Teruya-Feldstein J, Murakami M, Radimerski T, Michor F, Fan R, Levine RL.

Cancer Discov. 2015 Mar;5(3):316-31. doi: 10.1158/2159-8290.CD-14-0736. Epub 2015 Jan 8.

4.

Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes.

Oguro H, Yuan J, Tanaka S, Miyagi S, Mochizuki-Kashio M, Ichikawa H, Yamazaki S, Koseki H, Nakauchi H, Iwama A.

J Exp Med. 2012 Mar 12;209(3):445-54. doi: 10.1084/jem.20111709. Epub 2012 Feb 20.

5.

Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis.

Chorzalska A, Morgan J, Ahsan N, Treaba DO, Olszewski AJ, Petersen M, Kingston N, Cheng Y, Lombardo K, Schorl C, Yu X, Zini R, Pacilli A, Tepper A, Coburn J, Hryniewicz-Jankowska A, Zhao TC, Oancea E, Reagan JL, Liang O, Kotula L, Quesenberry PJ, Gruppuso PA, Manfredini R, Vannucchi AM, Dubielecka PM.

Blood. 2018 Nov 8;132(19):2053-2066. doi: 10.1182/blood-2018-05-848408. Epub 2018 Sep 13.

6.

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD Jr, Merker JD, Zehnder JL, Nolan GP, Gotlib J.

Blood. 2010 Aug 12;116(6):988-92. doi: 10.1182/blood-2010-02-270108. Epub 2010 Apr 19.

7.

Tat-NOL3 protects against hippocampal neuronal cell death induced by oxidative stress through the regulation of apoptotic pathways.

Sohn EJ, Shin MJ, Eum WS, Kim DW, Yong JI, Ryu EJ, Park JH, Cho SB, Cha HJ, Kim SJ, Yeo HJ, Yeo EJ, Choi YJ, Im SK, Kweon HY, Kim DS, Yu YH, Cho SW, Park M, Park J, Cho YJ, Choi SY.

Int J Mol Med. 2016 Jul;38(1):225-35. doi: 10.3892/ijmm.2016.2596. Epub 2016 May 19.

PMID:
27221790
8.

[Molecularly pathogenesis and molecular targeted therapy for myeloproliferative neoplasms].

Shide K.

Rinsho Ketsueki. 2015 Feb;56(2):150-8. doi: 10.11406/rinketsu.56.150. Review. Japanese.

PMID:
25765794
9.

Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.

Vainchenker W, Kralovics R.

Blood. 2017 Feb 9;129(6):667-679. doi: 10.1182/blood-2016-10-695940. Epub 2016 Dec 27. Review.

10.

Aspects biologiques de la voie JAK/STAT dans les néoplasmes myéloprolifératifs classiques négatifs pour BCR-ABL.

Mosca M, Vertenoeil G, Toppaldoddi KR, Plo I, Vainchenker W.

Bull Cancer. 2016 Jun;103(6 Suppl 1):S16-28. doi: 10.1016/S0007-4551(16)30142-4. Review. French.

PMID:
27494969
11.

p19(ARF) /p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma.

Schneller D, Machat G, Sousek A, Proell V, van Zijl F, Zulehner G, Huber H, Mair M, Muellner MK, Nijman SM, Eferl R, Moriggl R, Mikulits W.

Hepatology. 2011 Jul;54(1):164-72. doi: 10.1002/hep.24329.

PMID:
21452288
12.

Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.

Mak PY, Mak DH, Ruvolo V, Jacamo R, Kornblau SM, Kantarjian H, Andreeff M, Carter BZ.

Br J Haematol. 2014 Nov;167(3):376-84. doi: 10.1111/bjh.13054. Epub 2014 Jul 31. Erratum in: Br J Haematol. 2015 Nov;171(3):440.

13.

JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.

Wang X, Liu Q, Ihsan A, Huang L, Dai M, Hao H, Cheng G, Liu Z, Wang Y, Yuan Z.

Toxicol Sci. 2012 Jun;127(2):412-24. doi: 10.1093/toxsci/kfs106. Epub 2012 Mar 27.

PMID:
22454431
14.

Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation.

Nitulescu II, Meyer SC, Wen QJ, Crispino JD, Lemieux ME, Levine RL, Pelish HE, Shair MD.

EBioMedicine. 2017 Dec;26:112-125. doi: 10.1016/j.ebiom.2017.11.013. Epub 2017 Nov 21.

15.

Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice.

Yan D, Jobe F, Hutchison RE, Mohi G.

Leukemia. 2015 Oct;29(10):2050-61. doi: 10.1038/leu.2015.116. Epub 2015 May 18.

16.

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.

Kilpivaara O, Levine RL.

Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Epub 2008 Aug 28. Review.

PMID:
18754026
17.

SOCS3-mediated blockade of JAK/STAT3 signaling pathway reveals its major contribution to spinal cord neuroinflammation and mechanical allodynia after peripheral nerve injury.

Dominguez E, Mauborgne A, Mallet J, Desclaux M, Pohl M.

J Neurosci. 2010 Apr 21;30(16):5754-66. doi: 10.1523/JNEUROSCI.5007-09.2010.

18.

JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.

Treliński J, Robak T.

Curr Med Chem. 2013;20(9):1147-61.

PMID:
23317159
19.

Myeloproliferative neoplasms: A decade of discoveries and treatment advances.

Tefferi A.

Am J Hematol. 2016 Jan;91(1):50-8. doi: 10.1002/ajh.24221. Review.

20.

The EMT transcription factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling.

Li J, Riedt T, Goossens S, Carrillo García C, Szczepanski S, Brandes M, Pieters T, Dobrosch L, Gütgemann I, Farla N, Radaelli E, Hulpiau P, Mallela N, Fröhlich H, La Starza R, Matteucci C, Chen T, Brossart P, Mecucci C, Huylebroeck D, Haigh JJ, Janzen V.

Blood. 2017 Jan 26;129(4):460-472. doi: 10.1182/blood-2016-05-714659. Epub 2016 Sep 28.

Supplemental Content

Support Center